B
Bull
Bull · 25%PMCB
$0.97
Precio del escenario
$0.515
-0.024 (-4.66%)Al cierre
Loading chart…
- High
- 0.533
- Open
- 0.533
- VWAP
- 0.52
- Vol
- 83.34K
- Mkt Cap
- 17.58M
- Low
- 0.504
- Amount
- 43.11K
- EV/EBITDA, TTM
- 0.00
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
AI analysis of PharmaCyte Biotech Inc (PMCB)
sellPharmaCyte Biotech Inc is not a good buy right now due to its declining performance and negative financial metrics. The current price is $0.515, and the stock has seen a 30.22% decline year-to-date. Additionally, the RSI is at 31.15, indicating that the stock is oversold, but this does not necessarily imply a buying opportunity given the overall negative trend.
Métricas de valoración
The current forward P/E ratio for PharmaCyte Biotech Inc (PMCB) is 7.02, compared to its 5-year average forward P/E of -4.69.
Alphio AI Price Scenarios for PMCB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.511-26BenzingaAutodesk Shares Rise Approximately 6%; 20 Stocks Making Moves in Premarket Trading
7.511-25NewsfilterPharmaCyte Monetizes Femasys Stake, Boosts Cash to $20 Million
8.509-02NewsfilterPharmaCyte Biotech, Inc. Expands Investment in TNF Pharmaceuticals Following New License for Innovative Light Speed Computing Platform for Cryptocurrency Use
- 8.508-18Newsfilter
PharmaCyte Biotech, Inc. Secures $7 Million in Funding from Current Investors
- 7.0Newsfilter
NT 10-K Form - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 - PharmaCyte Biotech, Inc. (0001157075) (Filer)
PMCB FAQ — answered by Alphio AI
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
PharmaCyte Biotech Inc is not a good buy right now due to its declining performance and negative financial metrics. The current price is $0.515, and the stock has seen a 30.22% decline year-to-date. Additionally, the RSI is at 31.15, indicating that the stock is oversold, but this does not necessarily imply a buying opportunity given the overall negative trend.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.